NEW YORK (GenomeWeb) – Response Genetics today disclosed that its stock has been delisted from the Nasdaq and will now trade on the Over-the-Counter Bulletin Board.

In late December, the company said that its shares were facing delisting for failing to meet the Nasdaq's $1 minimum bid price requirement. The company had previously been notified that it also did not meet the exchange's minimum $2.5 million in stockholders’ equity requirement

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.

The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.

Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.

In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.